Dermapharm Holding SE (DMPHF) Stock Analysis

Dermapharm Holding SE (DMPHF) Healthcare & Pipeline Overview

Dermapharm Holding SE, headquartered in Germany, specializes in off-patent branded pharmaceuticals, over-the-counter drugs, and medical devices across dermatology, allergology, and other therapeutic areas. The company leverages three distinct segments—Branded Pharmaceuticals, Parallel Import, and Herbal Extracts—to serve pharmacies and hospitals internationally, maintaining a market capitalization of $2.36B.

What Is the Investment Thesis for DMPHF?

Dermapharm Holding SE presents an investment profile centered on its diversified portfolio of off-patent branded pharmaceuticals, OTC drugs, and medical devices, supported by a robust operational structure. The company's P/E ratio of 13.66 and a profit margin of 12.3% indicate a profitable enterprise within the healthcare sector. A gross margin of 42.7% highlights efficient production and pricing strategies. Key value drivers include the continuous expansion of its branded generics portfolio, capitalizing on patent expirations of established drugs, and the strategic growth of its Parallel Import Business which leverages market inefficiencies. The increasing global demand for natural remedies and supplements further supports the Herbal Extracts segment. With a market capitalization of $2.36B and a dividend yield of 1.85%, Dermapharm offers both growth potential and shareholder returns. The company's focus on therapeutic areas like dermatology and allergology, coupled with its medical device innovations, positions it to benefit from ongoing demographic shifts and rising healthcare needs. Its beta of 0.86 suggests lower volatility compared to the broader market, potentially appealing to investors seeking stability within the pharmaceutical industry.

Based on FMP financials and quantitative analysis

DMPHF Key Highlights

Market Capitalization: $2.36B, reflecting its substantial presence in the specialty and generic drug manufacturing sector.

• P/E Ratio: 13.66, indicating its earnings multiple relative to its share price, positioned within the broader healthcare industry.
• Profit Margin: 12.3%, demonstrating the company's efficiency in converting revenue into net income.
• Gross Margin: 42.7%, highlighting strong profitability from its core product sales before operating expenses.
• Dividend Yield: 1.85%, offering a return to shareholders through regular dividend payments.

Who Are DMPHF's Competitors?

DMPHF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are DMPHF's Key Strengths?

Diversified product portfolio across branded generics, OTC, medical devices, and natural extracts.

• Strong gross margin of 42.7% indicating efficient operations and pricing power.
• Integrated value chain from development to marketing.
• Established brands like Dekristol and Allergovit with market recognition.

What Are DMPHF's Weaknesses?

Reliance on off-patent pharmaceuticals, which can face intense generic competition.

• Potential exposure to pricing pressures in the parallel import business.
• Disclosure status on OTC market is 'Unknown,' which can deter some investors.
• Geographic concentration in Germany, despite international operations, may limit growth in saturated markets.

What Could Drive DMPHF Stock Higher?

DMPHF catalyst: Portfolio Expansion: The introduction of new off-patent branded pharmaceuticals or medical devices into key markets, potentially expanding Dermapharm's therapeutic reach and revenue streams.

• International Market Penetration: Continued efforts to expand sales and distribution channels in new international markets, particularly for its established brands and natural remedies, driving geographic diversification.
• Growth in Herbal Extracts Segment: Increasing consumer demand for natural health products could lead to higher sales volumes and market share for Dermapharm's herbal extracts and nutraceutical offerings.
• Strategic Partnerships: Formation of new collaborations or licensing agreements that could enhance product development, market access, or manufacturing capabilities for specific product lines.

What Are the Key Risks for DMPHF?

Inconsistent delivery — missed Wall Street EPS estimates in 1 of the last 6 reported quarters.

• Regulatory Changes: Adverse changes in pharmaceutical pricing, reimbursement policies, or drug approval processes in Germany or international markets could impact profitability.
• Intense Competition: The off-patent branded pharmaceuticals and generic drug markets are highly competitive, potentially leading to price erosion and margin pressure from rivals.
• Supply Chain Disruptions: Global supply chain vulnerabilities could affect the availability of raw materials for manufacturing or impact the efficiency of the parallel import business.
• OTC Market Limitations: The "OTC Other" listing and "Unknown" disclosure status may limit institutional investor interest and liquidity, potentially affecting share price stability.
• Product Liability: Risks associated with product recalls, adverse events, or litigation related to any of its pharmaceutical products, medical devices, or natural remedies.

What Are the Growth Opportunities for DMPHF?

• **Expansion of Branded Generics Portfolio**: Dermapharm has a significant opportunity to expand its portfolio of off-patent branded pharmaceuticals. As numerous blockbuster drugs face patent expiration in the coming years, the market for branded generics is projected to grow substantially, potentially reaching a global market size of over $400 billion by the early 2030s. By actively identifying and developing generic versions of these expiring patents, particularly in its established therapeutic areas like dermatology, allergology, and cardiovascular support, Dermapharm can capture new market share. This strategy leverages its existing manufacturing capabilities and distribution networks to introduce cost-effective alternatives, appealing to both healthcare providers and consumers seeking affordable, high-quality medications.
• **International Market Penetration**: While Dermapharm operates internationally, there is substantial room for deeper penetration into new and emerging markets beyond its core German base. Many regions, particularly in Eastern Europe, Asia, and Latin America, are experiencing rapid growth in healthcare expenditure and increasing demand for accessible pharmaceutical products. By strategically expanding its sales and distribution channels in these geographies, either through direct presence, partnerships, or acquisitions, Dermapharm can tap into new revenue streams. This expansion could focus on its well-known brands like Dekristol and Allergovit, leveraging their established efficacy and safety profiles to build trust in new markets, contributing to long-term revenue diversification.
• **Growth in Parallel Import Business**: The Parallel Import Business, operating under the axicorp brand, offers a unique growth avenue by capitalizing on price differentials of originator pharmaceuticals across different European Union member states. As healthcare systems continue to seek cost efficiencies, the demand for parallel-imported drugs remains robust. This segment can expand by broadening its product range, optimizing its sourcing and logistics networks, and enhancing its market intelligence to identify new arbitrage opportunities. The European parallel import market is a consistent segment, and by strengthening its operational excellence and regulatory compliance, Dermapharm can increase its market share and profitability within this specialized niche, contributing to overall group revenue.
• **Expansion of Herbal Extracts and Natural Products**: The global market for herbal extracts, phytopharmaceuticals, and nutraceuticals is experiencing significant growth, driven by increasing consumer preference for natural health solutions and preventive medicine. This market is projected to reach over $50 billion by the end of the decade. Dermapharm's Herbal Extracts segment is well-positioned to capitalize on this trend by expanding its range of natural active ingredients for both internal use (nutraceuticals) and external applications (cosmetics). Investing in research and development for new plant-based compounds, securing sustainable sourcing, and enhancing marketing efforts to health food stores and specialized retailers can unlock substantial growth, diversifying its revenue away from traditional pharmaceuticals.
• **Innovation and Diversification in Medical Devices**: The medical device market, particularly for consumer-oriented devices addressing common ailments, offers a promising growth trajectory. Dermapharm's existing products like bite away and Herpotherm demonstrate its capability in this area. Expanding this segment could involve developing new innovative devices for self-care, diagnostics, or therapeutic support in areas aligned with its pharmaceutical expertise, such as dermatology or pain management. The global medical device market is expected to continue its robust growth, driven by technological advancements and an aging population. By leveraging its brand recognition and distribution channels, Dermapharm can introduce new, user-friendly medical devices, enhancing its product ecosystem and capturing a larger share of the consumer health market.

What Are DMPHF's Competitive Advantages?

• **Diversified Product Portfolio**: A broad range of off-patent branded pharmaceuticals, OTC drugs, medical devices, and natural remedies reduces reliance on any single product or therapeutic area.
• **Integrated Value Chain**: Controls development, manufacturing, and marketing, allowing for greater quality control, cost efficiency, and faster market response.
• **Brand Recognition**: Established brands like Dekristol, Allergovit, and axicorp have built trust and recognition among healthcare professionals and consumers.
• **Specialized Market Niches**: Strong presence in specific therapeutic areas (e.g., dermatology, allergology) and the parallel import business creates specialized expertise and market positioning.
• **Regulatory Expertise**: Navigating the complex regulatory landscape for pharmaceuticals, medical devices, and natural products in Germany and internationally.

What Does DMPHF Do?

Dermapharm Holding SE, established in 1991 and headquartered in Grünwald, Germany, has evolved into a significant player in the off-patent branded pharmaceuticals sector, operating both domestically and internationally. The company's business model is structured around three core segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. Initially founded to develop and market pharmaceutical products, Dermapharm has steadily expanded its portfolio to include a diverse range of branded generics, over-the-counter (OTC) drugs, and non-prescription natural remedies. Its product offerings span critical therapeutic areas such as vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology. Key brands like Dekristol, Dekristolvit, Allergovit, and Tromcardin underscore its presence in these markets. Beyond pharmaceuticals, Dermapharm also innovates in medical devices, exemplified by products such as bite away and Herpotherm, alongside nasal sprays like Momekort for allergy symptoms and Azedil. The Parallel Import Business, operating under the axicorp brand, focuses on importing originator pharmaceuticals, capitalizing on price differentials across European markets. Furthermore, its Herbal Extracts segment is dedicated to providing natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics, tapping into the growing demand for natural health solutions. Dermapharm serves a broad customer base, including pharmaceutical wholesalers, pharmacies, hospitals, and health food stores, solidifying its market position as a comprehensive healthcare provider. The company operates as a subsidiary of Themis Beteiligungs-Aktiengesellschaft.

What Products and Services Does DMPHF Offer?

• Develops and manufactures off-patent branded pharmaceuticals, including branded generics and over-the-counter drugs.
• Produces non-prescription natural remedies and other healthcare products.
• Offers a range of products in therapeutic areas such as dermatology, allergology, cardiovascular support, and urology.
• Markets key brands including Dekristol, Dekristolvit, Allergovit, and Tromcardin.
• Provides medical devices like bite away and Herpotherm, as well as nasal sprays such as Momekort and Azedil.
• Engages in the parallel import of originator pharmaceuticals under the axicorp brand.
• Supplies herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics.
• Serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores.

How Does DMPHF Make Money?

• **Product Sales**: Generates revenue primarily through the sale of its self-developed and manufactured branded generics, OTC drugs, natural remedies, and medical devices.
• **Parallel Import**: Earns income by sourcing originator pharmaceuticals from lower-priced markets within the EU and selling them in higher-priced markets, leveraging price differentials.
• **Ingredient Supply**: Supplies herbal extracts and natural active ingredients to other manufacturers in the phytopharmaceutical, nutraceutical, and cosmetic industries.
• **Licensing and Marketing**: Engages in licensing agreements for certain products and actively markets its portfolio through established distribution channels.

What Industry Does DMPHF Operate In?

Dermapharm Holding SE operates within the dynamic Drug Manufacturers - Specialty & Generic industry, a segment characterized by the development, manufacturing, and marketing of off-patent drugs and specialized healthcare products. This industry is currently influenced by several key trends, including the increasing prevalence of chronic diseases, an aging global population driving demand for healthcare solutions, and growing cost-consciousness among healthcare systems, which favors generic and off-patent branded alternatives. Dermapharm's strategic focus on off-patent branded pharmaceuticals, OTC drugs, and natural remedies positions it to capitalize on these trends. The competitive landscape is fragmented, comprising large multinational pharmaceutical companies, specialized generic manufacturers, and regional players. Dermapharm differentiates itself through its integrated value chain, encompassing development, manufacturing, and marketing, alongside its diversified product portfolio across various therapeutic areas and its presence in the parallel import market. Its Herbal Extracts segment also taps into the expanding nutraceuticals market, offering a distinct competitive edge. The company's headquarters in Germany provides a strong base for its international operations, leveraging a well-regulated and mature pharmaceutical market.

Who Are DMPHF's Key Customers?

• Pharmaceutical wholesalers who distribute products to pharmacies and hospitals.
• Independent and chain pharmacies, serving as direct points of sale to consumers.
• Hospitals and clinics, utilizing Dermapharm's products for patient care.
• Health food stores and specialized retailers, for its natural remedies and food supplements.
• Other manufacturers in the phytopharmaceutical, nutraceutical, and cosmetic sectors for herbal extracts.

Dermapharm Holding SE (DMPHF) Valuation Context

Valued at $2.36B, DMPHF is classified as a mid-cap stock.

DMPHF Revenue & Earnings Trend

In Q2 FY2026, DMPHF generated $330.4M in top-line revenue, marking a sequential decrease of 7.2%. The company recorded net income of $26.9M, with diluted EPS of $0.55. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, DMPHF averaged $0.80 in diluted EPS.

Company Profile

Dermapharm Holding SE operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Grünwald, DE. The company is led by CEO Hans-Georg Feldmeier. DMPHF has traded publicly since 2022.

Return on equity for Dermapharm Holding SE stands at 21.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.3%, showing how much profit it generates from its asset base. DMPHF trades at a trailing price-to-earnings ratio of 13.66, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 8.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.00 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.7%, the inverse of the P/E and a quick read on earnings relative to price.

Dermapharm Holding SE's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.04 places it in the grey zone, a middle ground that warrants monitoring.

Dermapharm Holding SE has missed Wall Street's EPS estimate in 1 of its last 6 reported quarters — a mixed record worth weighing. Reported results have landed about 2.5% above estimates on average.

DMPHF Financials

DMPHF Latest News

No recent news available for DMPHF.

DMPHF Analyst Consensus

DMPHF MoonshotScore

What Investors Ask About Dermapharm Holding SE (DMPHF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources